Stockreport

POINT Biopharma Reports First Quarter 2022 Financial Results and Provides Business Update

POINT Biopharma Global Inc.  (PNT) 
PDF POINT's manufacturing facility initiated supply for the Phase 3 SPLASH trial. Randomization of patients for the SPLASH trial expanded to the European Union as scheduled. [Read more]